2005
Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease
Basso M, Gelernter J, Yang J, MacAvoy MG, Varma P, Bronen RA, van Dyck CH. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease. Neurobiology Of Aging 2005, 27: 1416-1424. PMID: 16182410, DOI: 10.1016/j.neurobiolaging.2005.08.002.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlzheimer DiseaseAmygdalaApolipoprotein E4Apolipoproteins EAtrophyBiomarkersFemaleHumansMaleOrgan SizeConceptsAlzheimer's diseaseAD patientsAPOE epsilon4AD groupImportant genetic risk factorApolipoprotein E epsilon4Regional brain atrophyAPOE epsilon4 alleleElderly control subjectsNormal elderly control subjectsGenetic risk factorsAmygdaloid volumesBrain atrophyControl subjectsEpsilon4 carriersRisk factorsEpsilon4 alleleHippocampal volumeEpsilon4 doseAnalysis of covarianceDisease severityPatientsEpsilon4AmygdalaAtrophy
2001
Neuroimaging in alzheimer’s disease: Relevance for treatment
van Dyck C. Neuroimaging in alzheimer’s disease: Relevance for treatment. Current Psychiatry Reports 2001, 3: 13-19. PMID: 11177754, DOI: 10.1007/s11920-001-0066-2.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseAD patientsRegional cerebral glucose metabolismRegional cerebral blood flowApolipoprotein E e4 alleleAnti-amyloid therapiesCerebral glucose metabolismDisease-modifying agentsCentral cholinergic neurotransmissionWhole brain atrophyCerebral blood flowPutative disease-modifying agentsWidespread clinical testingStructural magnetic resonanceBrain atrophyPrevention therapyInvestigational trialsAsymptomatic subjectsEfficacy measuresCholinergic neurotransmissionE4 alleleSenile plaquesDrug dosingOutcome measuresBlood flow